at the CNIO

Author: Sabio lab (Page 24 of 62)

Referentes que inspiran (3 Mar 2023)

Este 3 de marzo de 2023, Guadalupe Sabio participará en “Referentes que inspiran” en el Museo Nacional de Ciencia y Tecnología de La Coruña.

Esta jornada está organizada por el grupo de Mujer y Ciencia de la SEBBM, el propio Museo Nacional de Ciencia y Tecnología (MUNCYT) y Coruña Turismo.

La científica extremeña, Guadalupe Sabio, galardonada con el XXVII premio de biología molecular Carmen y Severo Ochoa

El próximo lunes la investigadora extremeña Guadalupe Sabio sumará a su brillante carrera un nuevo reconocimiento, el premio de investigación en biología molecular que otorga todos los años la Fundación Carmen y Severo Ochoa.

Guadalupe Sabio entrevistada en Canal Extremadura (9 de febrero de 2023).

Guadalupe Sabio trabajando en su laboratorio del CNIC.

The outcome of boosting mitochondrial activity in alcoholic liver disease (ALD) is organ-dependent

Naroa Goikoetxea-Usandizaga, Miren Bravo, Leire Egia-Mendikute, Leticia Abecia, Marina Serrano-Maciá, Rocío G Urdinguio, Marc Clos-García, Rubén Rodríguez-Agudo, Raquel Araujo-Legido, Lucía López-Bermudo, Teresa C Delgado, Sofía Lachiondo-Ortega, Irene González-Recio, Clàudia Gil-Pitarch, Ainize Peña-Cearra, Jorge Simón, Raquel Benedé-Ubieto, Silvia Ariño, Jose M Herranz, Mikel Azkargorta, Julio Salazar-Bermeo, Nuria Martí, Marta Varela-Rey, Juan M Falcón-Pérez, Óscar Lorenzo, Rubén Nogueiras, Félix Elortza Yulia A Nevzorova, Francisco J Cubero, Domingo Saura, Luis Alfonso Martínez-Cruz, Guadalupe Sabio, Asís Palazón, Pau Sancho-Bru, Natalia Elguezabal, Mario F Fraga, Matías A Ávila, Ramón Bataller, José J G Marín, Franz Martín & María Luz Martínez-Chantar.

Objective: Alcoholic liver disease (ALD) accounts for 70% of liver-related deaths in Europe, with no effective approved therapies. Although mitochondrial dysfunction is one of the earliest manifestations of alcohol-induced injury, restoring mitochondrial activity remains a problematic strategy due to oxidative stress. Here, we identify methylation-controlled J protein (MCJ) as a mediator for ALD progression and hypothesize that targeting MCJ may help recovering mitochondrial fitness without collateral oxidative damage.

Design: C57BL/6 mice (Wild-type (Wt), Mcj knockout (MCJ-KO) and Mcj liver-specific silencing (MCJ-LSS) underwent the NIAAA dietary protocol (Lieber-DeCarli diet containing 5% (vol/vol) ethanol for 10 days, plus a single binge ethanol feeding at day 11). To evaluate the impact of a restored mitochondrial activity in ALD, liver, gut, and pancreas where characterized, focusing on lipid metabolism, glucose homeostasis, intestinal permeability, and microbiota composition.

Results: MCJ, a protein acting as an endogenous negative regulator of mitochondrial respiration, is downregulated in the early stages of ALD and increases with the severity of the disease. Whole-body deficiency of MCJ is detrimental during ALD because it exacerbates the systemic effects of alcohol abuse through altered intestinal permeability, increased endotoxemia, and dysregulation of pancreatic function, which overall worsens liver injury. On the other hand, liver-specific Mcj silencing prevents main ALD hallmarks, i.e., mitochondrial dysfunction, steatosis, inflammation, and oxidative stress, as it restores the NAD+/NADH ratio and SIRT1 function, hence preventing de novo lipogenesis and improving lipid oxidation.

Conclusion: Improving mitochondrial respiration by liver-specific Mcj silencing might become a novel therapeutic approach for treating ALD.

« Older posts Newer posts »

© 2026 Sabio lab

Theme by Anders Norén — Up ↑